Indivior PLC
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INVVY research report →
About the company
Indivior PLC, encompassing its various subsidiaries, is a pharmaceutical firm dedicated to the research, production, and global commercialization of prescription medications. These therapies primarily utilize buprenorphine to treat opioid dependence and associated medical conditions. The company's development pipeline is actively exploring novel treatments for opioid use disorder (OUD) and schizophrenia.
- CEO
- Mark Crossley
- IPO
- 2015
- Employees
- 1,000
- HQ
- North Chesterfield, VA, US
Price Chart
- Market Cap
- $3.01B
- P/E
- 19.80
- P/S
- 3.85
- P/B
- -34.65
- EV/EBITDA
- 15.06
- Div Yield
- 0.00%
- Gross Margin
- 83.11%
- Op Margin
- 33.31%
- Net Margin
- 19.44%
- ROE
- -142.01%
- ROIC
- 85.68%
- Revenue
- $901.00M · 13.91%
- Net Income
- $-53,000,000 · -125.85%
- EPS
- $-0.36 · -125.53%
- Op Income
- $-91,000,000
- FCF YoY
- -103.13%
- 52W High
- $75.65
- 52W Low
- $14.76
- 50D MA
- $24.24
- 200D MA
- $21.39
- Beta
- -0.06
- Avg Volume
- 3.71K
Get TickerSpark's AI analysis on INVVY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our INVVY coverage
Recent articles, reports, and earnings notes.
No research on INVVY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INVVY report →Similar companies
Peers in the same neighborhood.